BioNTech SE (BNTX) Stock Forecast
BNTX analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.29 / 5 from 21 analysts
- Price target
- $117.07 average of analyst targets
- Upside to target
- +33.5% from the latest close
- Next earnings
- November 3, 2026 EPS estimate $0.85
- 52-week range
- $83.89 – $119.34
BNTX analyst ratings
21 analystsNumber of analysts at each rating.
BNTX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
BNTX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.76 | $0.42 | $1.35 | −$0.12 | +731.5% | 5 |
| Current fiscal year (2026) | −$4.71 | −$6.14 | −$4.04 | −$0.48 | −880.5% | 10 |
| Next fiscal year (2027) | −$5.00 | −$7.07 | −$3.07 | −$4.71 | −6.2% | 10 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
BNTX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $1.05B | $849.0M | $1.21B | −30.6% | 11 |
| Current fiscal year (2026) | $1.78B | $1.65B | $1.92B | −38.0% | 18 |
| Next fiscal year (2027) | $1.79B | $1.16B | $2.25B | +0.5% | 17 |
BNTX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
BNTX revenue: reported and forecast
BNTX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.66 | $0.76 | $0.76 | $0.76 | $0.76 | +15.4% | 3 up · 0 down |
| Current fiscal year (2026) | −$4.26 | −$4.97 | −$4.63 | −$4.60 | −$4.71 | +10.4% | 1 up · 2 down |
| Next fiscal year (2027) | −$4.33 | −$4.86 | −$4.90 | −$4.84 | −$5.00 | +15.5% | 1 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
BNTX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; BNTX beat in 4 of 12.
What analysts expect from BNTX
21 analysts cover BioNTech; their consensus rating is buy (4.29 on a 1–5 scale, where 5 is a strong buy). The average price target is $117.07, 33.5% above the latest close of $87.71. Analysts expect earnings of −$4.71 per share for 2026, −880.5% from a year earlier. For 2027 the average estimate is −$5.00 per share on revenue of $1.8 billion. BioNTech beat the EPS estimate in 4 of the last 12 quarters.
Related: BNTX income statement, BNTX key metrics, BNTX chart. See the BNTX stock overview for the latest quote and news.
BNTX forecast FAQ
What is BioNTech's price target?
The average analyst price target for BioNTech is $117.07, 33.5% above the latest close of $87.71.
Is BioNTech a buy, hold or sell?
Of 21 analysts covering BioNTech, 13 rate it a strong buy, 1 a buy, 7 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is BioNTech's EPS forecast?
Analysts forecast −$4.71 per share for 2026 (range −$6.14 to −$4.04); for 2027 the estimate is −$5.00.
What is BioNTech's revenue forecast?
The average revenue estimate for 2026 is $1.8 billion, growth of −38.0%; for 2027 it is $1.8 billion.
When does BioNTech report earnings?
BioNTech is expected to report results for the quarter ending September 30, 2026 on November 3, 2026 before the market opens; the EPS estimate is $0.85.
Does BioNTech usually beat earnings estimates?
BioNTech reported EPS at or above the analyst estimate in 4 of the last 12 quarters.